Bringing the fundamentals into focus…
Back to NovaBridge Biosciences
How NovaBridge Biosciences stacks up
NBP · against 111 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #49 of 112 · scores higher than 40% of peers
Bars: peers in each 10-point band of the valuation score33 peers with a valuation score of 30–39, including NBP · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -19.8% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -8.8% vs peer median 0.0%
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
Metric by metric
Position: dot = NBP, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NBP | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 96 reported | -68.3% | -12.4% | 20% | 30% | |
| EBITDA yieldHigher is better · 119 reported | 590.2% | -1.8% | 97% | 50% | |
| Free cash flow yieldHigher is better · 84 reported | Not reported | -15.8% | — | — | 20% |
| Book yieldHigher is better · 100 reported | 171.7% | 70.9% | 86% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around NBP| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 49 | 216M USD | 33 | 44 | |
| 49 | 126M USD | 33 | 32 | |
| 49 | 215M USD | 33 | 34 | |
| 49 | 110M USD | 33 | 54 | |
| 49 | 117M USD | 33 | 40 | |
| 49 | 149M USD | 33 | ||
| 49 | 191M USD | 33 | 38 | |
| 49 | 165M USD | 33 | 50 | |
| 49 | 158M USD | 33 | 14 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score